ASP
PVLA

Adams Street Partners’s Palvella Therapeutics PVLA Stock Holding History

Adams Street Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-298,986
Closed -$6.74M – 7
2025
Q2 		$6.74M Sell
298,986
-110,680
-27% -$2.6M 4.75% 5
2025
Q1 		$11.5M Hold
409,666
– – 10.15% 2
2024
Q4 		$4.92M Buy
+409,666
New +$6.43M 4.36% 5

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adams Street Partners's PVLA Position: Q3 2025 in Review

Adams Street Partners sold out of Palvella Therapeutics (PVLA) in Q3 2025, closing a stake of 298,986 shares — an estimated $6.74M sold.

Adams Street Partners first reported a position in PVLA in Q4 2024 and held it in 3 quarters. The position peaked at $11.5M in Q1 2025. 100 funds tracked by Wall St. Rank hold PVLA as of Q3 2025.

  • Adams Street Partners reported no remaining Palvella Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Adams Street Partners sold 298,986 Palvella Therapeutics shares in Q3 2025, an estimated $6.74M.
  • Adams Street Partners first reported a position in Palvella Therapeutics in Q4 2024 and held it in 3 quarters.
  • Adams Street Partners's Palvella Therapeutics position peaked at $11.5M in Q1 2025.
  • 100 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2025.

Based on Adams Street Partners's 13F filing for Q3 2025, filed 14 Nov 2025.